Navigation Links
3SBio Inc. Schedules 2007 Fourth Quarter and Full Year Earnings Release on Wednesday, February 20, 2008
Date:2/11/2008

Earnings Conference Call to be held on Thursday, February 21, 2008 at 5:00

am (Pacific) / 8:00 am (Eastern) / 9:00 pm (Beijing/Hong Kong)

SHENYANG, China, Feb. 11 /PRNewswire-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it will release unaudited financial results for the fourth quarter and full year ended December 31, 2007 after the US market closes on Wednesday, February 20, 2008.

The earnings release will be available on the investor relations page of its website at http://www.3sbio.com/en/News/ShowInfo_nnn11.aspx?ID=71.

Following the earnings announcement, 3SBio Inc. senior management will host a conference call at 5:00 am (Pacific) / 8:00 am (Eastern) / 9:00 pm (Beijing/Hong Kong) on Thursday, February 21, 2008 to discuss its 2007 fourth quarter and full year financial results and recent business activity. The conference call may be accessed by calling (US) +1 480 629 9041/ (UK) + 44 20 8515 2301/ (HK) + 852 3009-5027. A telephone replay will be available shortly after the call until March 6, 2008 at (US) +1 303 590 3030/ (UK) + 44 207 154 2833, Passcode: 3839328; and (HK) + 852 2287 4304, Passcode: 104110#

A live webcast of the conference call and replay will be available on the investor relations page of 3SBio's website at http://www.3sbio.com/en/News/ShowInfo_nnn11.aspx?ID=71.

About 3SBio Inc.

3SBio Inc. is a leading, fully integrated biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, primarily in China. For more information, please visit 3SBio on the web at http://www.3sbio.com<
'/>"/>

SOURCE 3SBio Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. 3SBio Inc. to Present at the UBS Global Life Sciences Conference
2. 3SBio Inc. to Hold Annual General Meeting
3. 3SBio Inc. Schedules 2007 Third Quarter Earnings Release On Tuesday, November 13, 2007
4. 3SBio Inc. To Present at the 19th Annual Piper Jaffray Health Care Conference
5. 3SBio Inc. Announces Appointment of Kevin Sow Peng Teo as Chief Financial Officer
6. 3SBio Inc. to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
7. WuXi PharmaTech Schedules 2007 Second Quarter Earnings Release on Thursday, September 6, 2007
8. LifeCell Corporation Schedules Third Quarter 2007 Financial Results Conference Call; October 25, 2007 at 10:00 A.M. Eastern
9. WorldHeart Schedules Teleconference
10. LifeCell Corporation Schedules 2008 Financial Guidance Release and Conference Call; January 7, 2008 at 10:00 A.M. Eastern
11. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... (PRWEB) January 22, 2015 Selexis SA, ... mammalian Research Cell Banks (RCBs) used for drug discovery ... Cell Banks will include Next-Generation Sequencing (NGS) ... architecture de-risks biologic manufacturing by ensuring the integrity of ...
(Date:1/22/2015)... CAMBRIDGE, Mass. , Jan. 22, 2015   GenoSpace , ... suite of tools to enable the broad use of genomic, ... today announced the appointment of Michelle Munson , CEO ... independent director. Logo - http://photos.prnewswire.com/prnh/20150122/170713 ...
(Date:12/24/2014)... 24, 2014  Vermillion, Inc. (Nasdaq:   VRML), a ... today that the Company closed its previously announced ... Jack W. Schuler , Birchview Fund LLC ... million, before offering expenses.  The proceeds will be ...
(Date:12/24/2014)... BOSTON, MA (PRWEB) December 23, 2014 ... series is designed to introduce cutting edge communication ... partners of platform upgrades. This webinar series demonstrates ... their quest to leverage web conferencing’s most innovative ...
Breaking Biology Technology:Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2GenoSpace Expands Board with Appointment of Michelle Munson 2Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3
... Study Results for Memory and Cognition Validate Clinical ... ... Amarin Corporation plc,(NASDAQ: AMRN ) ("Amarin" or "Company") announced ... using ultra-pure,eicosapentanoic acid (EPA) have been published in the "Journal ...
... Sample Analysis Systems-, PHILADELPHIA, Sept. 24 ... whole genome imaging and analytic,platforms for clinical ... the issuance of a patent for a ... The patent covers a novel technique for,the ...
... Shire management team, CAMBRIDGE, Mass., and ... SHP, Nasdaq: SHPGY, TSX: SHQ),the global specialty ... been appointed President of its Human Genetic ... than 20 years of,management, regulatory affairs, manufacturing ...
Cached Biology Technology:Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry 2Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry 3Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry 4Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry 5BioNanomatrix Announces Issuance of Key Nanofluidics Patent Enabling Single Molecule Whole Genome Analysis 2BioNanomatrix Announces Issuance of Key Nanofluidics Patent Enabling Single Molecule Whole Genome Analysis 3Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business 2Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business 3Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business 4
(Date:1/22/2015)... TORONTO , Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the ... announced the launch of its new website design. ... in its infancy", says Peter O,Neill , founder and ... ever, the industry needs involvement from the key players on ...
(Date:1/22/2015)... Jan. 13, 2015 Technology Showcase, Hall E -   ... solutions, today announced it will showcase its EyeLock ID technology ... the Department of Energy,s Oak Ridge National Laboratory ... . EyeLock,s iris identity authentication technology is being used to ...
(Date:1/22/2015)...  A man-made form of insulin delivered by nasal spray ... adults with mild cognitive impairment and Alzheimer,s disease dementia, ... Wake Forest Baptist Medical Center. The study,s ... impairment (MCI) or mild to moderate Alzheimer,s dementia (AD). ...
Breaking Biology News(10 mins):Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3
... first clinical evidence that gene therapy reduces symptoms in ... promising treatment which has endured a sometimes turbulent past. ... Human Gene Therapy the findings stem from a ... in Germany and led by an investigator at Beth ...
... -- Across the globe, the demand for water is ... urban areas are requiring more water for drinking, sanitation, ... supplies. In addition, depleting ground water, longer droughts, and ... increased importance for the agricultural industry to optimize irrigation, ...
... could save thousands of lives a year, University of Utah ... disorder leading to unpredictable, sometimes fatal, hemorrhagic strokes, seizures, paralysis ... that millions of people take to control high cholesterol. ... in a pilot trial with people, statins could provide a ...
Cached Biology News:Gene therapy demonstrates benefit in patients with rheumatoid arthritis 2Gene therapy demonstrates benefit in patients with rheumatoid arthritis 3How to move agriculture forward with limited water 2Statins may treat blood vessel disorder that can lead to fatal strokes 2Statins may treat blood vessel disorder that can lead to fatal strokes 3
Comp Dim: chamber diam. depth 20 2.8 mm chamber maximum volume 720 μL...
... vitro diagnostic assays, all EIA/RIA plates are ... binding, high optical clarity and low background ... of the Certified Surface Chemistry Programme, which ... QA release specifications. Linkage: This CLS number ...
... clarification reagent; Ideal for clarifying many ... proteins, nucleic acids, & proteoglycans; Contains ... improves downstream processing; Utilizes a reagent ... supplied as a suspension in saline; ...
... The lyophilization stabilizer is designed to ... and for long-term storage. There ... ingredients. It is a convenient ... 7.2, and is superior to other ...
Biology Products: